Want to see AU:CHM full AI Analyst Report?
Chimeric Therapeutics Ltd. (CHM) Drug Pipeline
| Drug Name | Condition | Stage | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Chm-2101 Car-T Cells | Colorectal Cancer, Gastric Cancer, Neuroendocrine Tumors | phase1AndPhase2 | Recruiting | A Phase 1/2 Study to Evaluate CHM-2101, an Autologous Cadherin 17 Chimeric Antigen Receptor (CAR) T Cell Therapy | Sep 13, 2023 | ― |
| Chm-1101 Car-T Cells | Glioblastoma Multiforme Of Brain | Phase I | Active Not Recruiting | CAR T Cells in Patients With MMP2+ Recurrent or Progressive Glioblastoma | Nov 16, 2022 | ― |
| Drug Name | Stage | Condition | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Chm-2101 Car-T Cells | phase1AndPhase2 | Colorectal Cancer, Gastric Cancer, Neuroendocrine Tumors | Recruiting | A Phase 1/2 Study to Evaluate CHM-2101, an Autologous Cadherin 17 Chimeric Antigen Receptor (CAR) T Cell Therapy | Sep 13, 2023 | ― |
| Chm-1101 Car-T Cells | Phase I | Glioblastoma Multiforme Of Brain | Active Not Recruiting | CAR T Cells in Patients With MMP2+ Recurrent or Progressive Glioblastoma | Nov 16, 2022 | ― |
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Chimeric Therapeutics Ltd. (AU:CHM) have in its pipeline
Chimeric Therapeutics Ltd. AU:CHM is currently developing the following drugs: Chm-2101 Car-T Cells, Chm-1101 Car-T Cells. These drug candidates are in various stages of clinical development as the company works toward FDA approval.